ClinicalTrials.Veeva

Menu

Study of Efficacy of Oxcarbazepine in Therapy of Bronchial Asthma

C

Centre of Chinese Medicine, Georgia

Status and phase

Completed
Phase 4

Conditions

Bronchial Asthma

Treatments

Drug: Oxcarbazepine

Study type

Interventional

Funder types

Other

Identifiers

NCT00142025
LP-0501-OC-0302

Details and patient eligibility

About

The purpose of this study is to determine whether antiepileptic drug oxcarbazepine is effective in the treatment of chronic asthma.

Full description

Effective therapy of asthma still remains quite serious problem. According GINA definition, asthma is an inflammatory disorder. Consequently, modern pharmacotherapy of asthma provides wide use of anti-inflammatory drugs. But asthma also is a paroxysmal disorder: many specialists and even some guidelines underline paroxysmal clinical picture of asthma. Besides this, according to some authors, neurogenic inflammation may play important role in asthma mechanism. But some other neurogenic inflammatory paroxysmal disorders exist, and they are migraine and trigeminal neuralgia. Some antiepileptic drugs, like carbamazepine and valproate, are very effective in therapy of migraine and trigeminal neuralgia - more than in 80% of cases. If bronchial asthma also is paroxysmal inflammatory disease, like migraine and trigeminal neuralgia, it is possible that some antiepileptic drugs also are very effective in asthma therapy.

We performed a double-blind, placebo-controlled 3-month trial for evaluation of oxcarbazepine efficacy in therapy of bronchial asthma. Oxcarbazepine is antiepileptic drug of new generation, produced by Novartis, and it is more effective and safe derivative of well-known antiepileptic drug carbamazepine.

Comparison: Patients received investigational drug in addition to their usual routine antiasthmatic treatment, compared to patients received placebo in addition to their usual routine antiasthmatic treatment.

Sex

All

Ages

17 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Bronchial asthma has been known at least for 1 year
  • Absence of long-term remissions of asthma (lasting more than 1 month)
  • Poorly controlled asthma, due to various reasons
  • Non-smokers

Exclusion criteria

  • Presence of concomitant severe diseases
  • Allergy or adverse reactions to carbamazepine or oxcarbazepine
  • Abnormal baseline haematology, blood chemistry or urinalysis
  • Current use of long-acting beta-agonists
  • Age younger than 16 years old
  • Long-term history of smoking
  • Pregnancy or lactating

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems